Edition:
United Kingdom

Heron Therapeutics Inc (HRTX.OQ)

HRTX.OQ on NASDAQ Stock Exchange Capital Market

15.55USD
15 Dec 2017
Change (% chg)

$0.15 (+0.97%)
Prev Close
$15.40
Open
$15.50
Day's High
$15.75
Day's Low
$15.40
Volume
649,710
Avg. Vol
165,661
52-wk High
$18.35
52-wk Low
$12.25

Select another date:

Tue, Dec 5 2017

BRIEF-Heron Therapeutics Announces Pricing Of Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Heron Therapeutics Announces Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

BUZZ-Heron Therapeutics: FDA approves chemotherapy-induced nausea drug

** Drug developer's shares rise 4.9 pct to $18.20 after market

BRIEF-Heron Therapeutics gets FDA approval for Cinvanti

* Announces U.S. FDA approval of Cinvanti™ (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv)

BRIEF-Heron Therapeutics reports qtrly diluted net loss per share $0.77

* Heron Therapeutics reports financial results for the three and nine months ended September 30, 2017 and recent corporate progress

BRIEF-Heron Therapeutics granted FDA fast track designation for HTX-011

* Heron Therapeutics granted FDA fast track designation for HTX-011 to reduce postoperative pain and the need for opioid analgesics for 72 hours

BRIEF-Heron Therapeutics initiates phase 3 program for HTX-011

* Heron Therapeutics announces initiation of phase 3 program for HTX-011 in postoperative pain following successful end-of-phase 2 meeting with FDA

BRIEF-Heron Therapeutics reports quarterly loss per share $0.80

* Heron Therapeutics reports financial results for the three and six months ended June 30, 2017 and recent corporate progress

Select another date: